THE EFFECT OF NICOTINIC-ACID AND ACIPIMOX ON LIPOPROTEIN(A) CONCENTRATION AND TURNOVER

被引:87
作者
SEED, M
OCONNOR, B
PEROMBELON, N
ODONNELL, M
REAVELEY, D
KNIGHT, BL
机构
[1] CHARING CROSS & WESTMINSTER MED SCH,DEPT MED,LONDON,ENGLAND
[2] HAMMERSMITH HOSP,MRC,LIPOPROT TEAM,LONDON W12 0HS,ENGLAND
[3] CHARING CROSS & WESTMINSTER MED SCH,DEPT CHEM PATHOL,LONDON,ENGLAND
关键词
LIPOPROTEIN LP (A); NICOTINIC ACID; IN-VIVO TURNOVER; APO(A) ISOFORMS; ACIPIMOX;
D O I
10.1016/0021-9150(93)90102-Z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study examines the effect of nicotinic acid (1 g t.d.s.) on serum Lp(a) concentration in a group of patients with type II hyperlipidaemia selected on the basis of a plasma Lp(a) concentration greater than 30 mg/dl. Reductions in total cholesterol, triglyceride, LDL-cholesterol and Lp(a) were 16.3%, 25.5%, 23.7% and 36.4%, respectively, with an increase in HDL cholesterol of 37.3%. The reduction in Lp(a) concentration did not correlate with any other lipoprotein changes. In order to establish the mechanism of the fall in Lp(a) concentration, in vivo turnover of autologous Lp(a) was studied in three subjects before and whilst taking nicotinic acid. The fractional catabolic rate in Lp(a) was unaltered in the subjects on therapy, indicating that nicotinic acid did not increase catabolism of Lp(a) but decreased the synthetic rate. Since nicotinic acid was poorly tolerated we examined the effect of acipimox, an analogue of nicotinic acid on lipoproteins using a placebo controlled double-blind crossover design in a group of hyperlipidaemic patients again selected with plasma Lp(a) concentration greater than 30 mg/dl. Acipimox was better tolerated than nicotinic acid but the percentage changes in lipoprotein concentrations were smaller.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 27 条
[1]   REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL [J].
ALBERS, JJ ;
TAGGART, HM ;
APPLEBAUMBOWDEN, D ;
HAFFNER, S ;
CHESNUT, CH ;
HAZZARD, WR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 795 (02) :293-296
[2]  
[Anonymous], 1956, NONPARAMETRIC STAT B
[3]   THE ASSOCIATION BETWEEN SERUM LP(A) CONCENTRATIONS AND ANGIOGRAPHICALLY ASSESSED CORONARY ATHEROSCLEROSIS - DEPENDENCE ON SERUM LDL LEVELS [J].
ARMSTRONG, VW ;
CREMER, P ;
EBERLE, E ;
MANKE, A ;
SCHULZE, F ;
WIELAND, H ;
KREUZER, H ;
SEIDEL, D .
ATHEROSCLEROSIS, 1986, 62 (03) :249-257
[4]   REDUCTION IN CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN SYNTHESIS AFTER PORTACAVAL-SHUNT SURGERY IN A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
BILHEIMER, DW ;
GOLDSTEIN, JL ;
GRUNDY, SM ;
BROWN, MS .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (06) :1420-1430
[5]  
BLACK IW, 1992, CLIN CHEM, V38, P353
[6]   GENETICS OF THE QUANTITATIVE LP(A) LIPOPROTEIN TRAIT .3. CONTRIBUTION OF LP(A) GLYCOPROTEIN PHENOTYPES TO NORMAL LIPID VARIATION [J].
BOERWINKLE, E ;
MENZEL, HJ ;
KRAFT, HG ;
UTERMANN, G .
HUMAN GENETICS, 1989, 82 (01) :73-78
[7]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[8]  
BURSTEIN M, 1970, J LIPID RES, V11, P583
[9]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[10]   PRONOUNCED LOWERING OF SERUM LEVELS OF LIPOPROTEIN LP(A) IN HYPERLIPEMIC SUBJECTS TREATED WITH NICOTINIC-ACID [J].
CARLSON, LA ;
HAMSTEN, A ;
ASPLUND, A .
JOURNAL OF INTERNAL MEDICINE, 1989, 226 (04) :271-276